For pharmaceutical, animal health and medical device organisations, preparing for and working through regulatory inspections or audits from the TGA, APVMA, ACVM and Medsafe can be harrowing. Whether your organisation is large or small, there is a tremendous amount of (virtual and perceived) pressure. Regulators will find deficiencies but the better prepared your organisation is, the smaller the chance of the findings being critical or major. This course will help you navigate regulatory inspections / audits by arming you with tools and methods to best prepare.

“Success is where preparation and opportunity meet” (Bobby Unser)

Regulatory audit of facility

Content

This course will address the key areas that you must focus on when preparing for a regulatory inspection. It will dive into the differences between approaches of the US FDA, EU and TGA, and how to best handle responses to observations / findings from a GMP Inspection. Differences you will encounter in remote inspections (compared to on-site inspections) will also be covered. There is also a section on what to expect from the Pharmacovigilance Inspection Program (PVIP).

  • Legal requirements of inspections and some differences between International Inspectors and TGA Inspectors
    • Access to site
    • Collection of evidence including photographs
    • Viewing of internal inspection reports
  • Things to get ready
  • Remote Inspection vs Onsite
  • “War Room” protocol
  • Using Subcontractors and Knowing the Starting Point of Manufacture
  • Preparation for New Licence vs Routine Re-Inspection
  • Opening Meeting, Daily Wrap Up and Closing Meeting
  • Closeout
  • Pharmacovigilance Inspection Program (PVIP)
Participants

This course has been designed for all staff who will be involved in regulatory audits; for example, Quality Assurance, Quality Control, Manufacturing, Validation and Engineering personnel. You might expect to speak directly with the Regulator, or you might work behind the scenes gathering requested documents and records.

Format and Course Length

The course will be delivered as an online virtual-classroom training session.

Participants will be provided with a PDF of the training material in advance of the training should they wish to print and annotate notes. Participants will be connected to the trainer and other participants via online collaboration tool Zoom with connected video (webcam / screen sharing) and audio (computer audio or phone dial-in). Theory will be delivered by the trainer sharing their screen of the PowerPoint presentation. Facilitated workshops will be run in digital breakout rooms (e.g. a group of 12 might split into 3 breakout rooms each with 4 participants to separately work on a problem). Breakout rooms can call the trainer in for support when required and the trainer can electronically bring everyone back to the main session to debrief when appropriate.

The training is delivered as 2 x 3.5 hour sessions over 2 days. Breaks are included.

A digital credential (badge) will be issued via Credly on e-mail to recognise successful training completion.

What Do I Need?

Participant needs are very basic. You will need a computer or suitable device with a good internet connection. A headset (headphones with microphone) and second monitor/screen are recommended but not required.

Sessions

Participants will attend both half-day sessions:

 Session  Dates  Times
 Day 1  31st May 2022  9:00am-12:30pm
Day 2  1st June 2022  9:00am-12:30pm

Times are based on Melbourne, Australian Eastern Standard Time (AEST) / Coordinated Universal Time (UTC) +10:00

Fee and Discount
  • AUD $650 (excluding GST) per participant; introductory offer
    • A 10% discount applies for 3 or more participants from the same company

New Session Dates To Be Advised

Contact us to discuss your interest in a public or private delivery of this course.

Refer to the Terms and Conditions

Andrew Giles Profile

Proposed Trainer

Andrew Giles

Andrew has over 30 years of experience in the pharmaceutical industry including more than 11 years as a Medicines Inspector with the Therapeutic Goods Administration (TGA) of Australia. During his time with the TGA Andrew was lead inspector for initial, routine and special inspections of Australian and international facilities that produced sterile and non-sterile medicines as prescription medicines, Over The Counter (OTC) medicines, complimentary medicines, sunscreens, veterinary products and Active Pharmaceutical Ingredients (API). Andrew has had experience in dosage forms including injectable, biologicals, radiopharmaceuticals, compounding, oral dosage forms and sprays. Andrew has also worked with inspectors from other agencies and been part of, and lead for, multinational inspection teams.